Genetic Testing for Inheritable Cardiac Channelopathies
Inheritable cardiac channelopathies (ICC) are defined as primary electrical disorders without identifiable cardiac structural abnormalities and are mostly encountered in young adults (under 40 years). Diagnosis of ICC is often established after the first symptoms such as recurrent palpitations and syncope or more dramatically after unexplained sudden cardiac death (SCD). In this context, familial clinical screening coupled with genetic testing are required to prevent additional (fatal) arrhythmia events in relatives. This review presents an update of the ICC-associated genes and proposes a screening hierarchy according to the phenotype. The impact of the new sequencing technologies on the genetic testing as well as on the patient management will be also discussed.
Compliance with Ethical Standards
Sources of Funding
Julien Barc was supported by the H2020-MSCA-IF-2014 Program of the European Commission (RISTRAD-661617).
Conflict of Interest
Florence Kyndt declares that she has no conflict of interest. Jean-Baptiste Gourraud declares that he has no conflict of interest. Julien Barc declares that he has no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European heart rhythm association (EHRA). Europace. 2011;13:1077–109.PubMedPubMedCentralCrossRefGoogle Scholar
- Barsheshet A, Goldenberg I, O-Uchi J, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation. 2012;125:1988–96.PubMedPubMedCentralCrossRefGoogle Scholar
- Crotti L, Spazzolini C, Schwartz PJ, et al. The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation. 2007;116:2366–75.PubMedCrossRefPubMedCentralGoogle Scholar
- Crotti L, Marcou CA, Tester DJ, et al. Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol. 2012;60:1410. Available at: PM:22840528PubMedPubMedCentralCrossRefGoogle Scholar
- Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19(2):249–55.PubMedCrossRefPubMedCentralGoogle Scholar
- Mayosi BM, Fish M, Shaboodien G, et al. Identification of cadherin 2 (CDH2) mutations in arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet. 2017;10Google Scholar
- Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol. 2009;54:2065–74.PubMedPubMedCentralCrossRefGoogle Scholar
- Pagon RA, Adam MP, Ardinger HH, et al. GeneReviews(®). Seattle: University of Washington; 1993.Google Scholar
- Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm. 2009;6:1335–41.
- Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and Management of Patients with inherited primary arrhythmia syndromes expert consensus statement on inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in may 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;19:e75. Available at: PM:24011539Google Scholar
- Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793–867.PubMedCrossRefPubMedCentralGoogle Scholar
- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.PubMedPubMedCentralCrossRefGoogle Scholar
- Romano C, Gemme G, Pongiglione R. Rare cardiac arrythmias of the pediatric age. II. Syncopal attacks due to paroxysmal ventricular fibrillation (presentation of 1st case in Italian pediatric literature). Clin Pediatr (Bologna). 1963;45:656–83.Google Scholar
- Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. 2007;115:1710–20.PubMedCrossRefPubMedCentralGoogle Scholar
- Tully I, Atherton J, Hunt L, Ingles J, Semsarian C, McGaughran J. Rarity and phenotypic heterogeneity provide challenges in the diagnosis of Andersen-Tawil syndrome: two cases presenting with ECGs mimicking catecholaminergic polymorphic ventricular tachycardia (CPVT). Int J Cardiol. 2015;201:473–5.PubMedCrossRefPubMedCentralGoogle Scholar
- Ward OC. A new familial cardiac syndrome in children. J Irish Med Assoc. 1964;54:103–6.Google Scholar